|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy.
|
10567494 |
1999 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 and Bax genes are probably involved in the reduction of malignancy of glioblastoma cell caused by the introduction of EGFR-antisense into these tumor cells.
|
10628370 |
2000 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 and the closely related Bcl-xL and Mcl-1 are often overexpressed in glioblastoma cells.
|
26775694 |
2016 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo.
|
18663354 |
2008 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Accumulating evidence indicates that resistance to apoptosis in GB is mediated via upregulation of pro-survival BCL2-family members.
|
30389373 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL.
|
9576258 |
1998 |
|
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
|
21250804 |
2011 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
CD133 (stem marker) and drug resistant gene (mdr1 and bcl-2) expression were detected in human glioblastoma and normal brain tissues.
|
18568776 |
2008 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD133 (stem marker) and drug resistant gene (mdr1 and bcl-2) expression were detected in human glioblastoma and normal brain tissues.
|
18568776 |
2008 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme.
|
23076250 |
2013 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CTRP8-induced RXFP1 activation caused an increase in cellular protein levels of the anti-apoptotic Bcl members and STAT3 targets Bcl-2 and Bcl-XL in human GBM.
|
29949238 |
2018 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
|
11083075 |
2000 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulation of Bcl-xL and Bcl-2 with DNA antisense oligonucleotides promotes cell death in glioblastoma cells.
|
15332326 |
2004 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of bcl-2 and bcl-xl expression in glioblastoma cells can induce apoptosis.
|
19267218 |
2010 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
|
30337641 |
2018 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated ZHX1 expression correlated with poor prognosis in GBM patients, and in vitro studies demonstrated that ZHX1 attenuated GBM cell apoptosis by downregulation of pro-apoptotic protein (Bax) and upregulation of anti-apoptotic protein (Bcl-2).
|
31648104 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the first time, our results showed that LRIG1 can enhance chemosensitivity in glioblastoma by inhibition of BCL-2 and MnSOD.
|
25449296 |
2015 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression levels of the Bcl-2 anti-apoptotic protein was significantly decreased while Bax and caspase-3 expression were both increased in glioblastoma cells (all, p<0.05).
|
29940755 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gemistocytes showed a significantly higher bcl-2 expression than all tumor cells, with a mean bcl-2 1 of 15.6% versus 2.7% in low-grade astrocytomas (p = 0.0004), 20.9% versus 3.0% in anaplastic astrocytoma (p = 0.002), and 30.2% versus 5.2% in glioblastomas (p = 0.0002).
|
9042164 |
1997 |
|
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we identify Bcl2-like 13 (Bcl2L13), an atypical member of the Bcl-2 family, as a therapy susceptibility gene with elevated expression in solid and blood cancers, including glioblastoma (GBM).
|
24706805 |
2014 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High steady-state levels of Bcl-2 were identified as potentially accounting for the resistance of a proportion of glioblastoma lines to factors secreted by activated CTLs.
|
20483178 |
2010 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hypoxic regions of GBM also highly express the pro-cell death Bcl-2 family member BNIP3, yet when BNIP3 is overexpressed in glioma cells, it induces cell death.
|
26467103 |
2016 |
|
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immunolabelling with the bcl-2 antibody was found in 44% of fibrillary astrocytomas, 42% of anaplastic astrocytomas, and 28% of glioblastomas.
|
7494604 |
1995 |
|
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the BCL2-938AA genotype was significantly more common in patients with glioblastoma and in patients with grade IV glioma.
|
24287948 |
2014 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicate that the combination of taxol and Bcl-2 siRNA effectively induces apoptosis and inhibits glioblastoma cell invasion, angiogenesis and intracranial as well as subcutaneous tumour growth.
|
19473291 |
2009 |